With more than two decades of experience at global pharmaceutical, biotechnology and medical device companies, Michael Magee has been appointed as vice president, quality and compliance, at Monmouth Junction-based Tris Pharma Inc.
“Michael joins Tris Pharma at an incredibly exciting time in which we have an established portfolio of ADHD medications and a diverse pipeline of late-stage assets, and where his proven track record in the pharmaceutical industry will play a key role in further enhancing our ongoing quality assurance and compliance initiatives,” Ketan Mehta, founder and CEO of Tris Pharma, said. “With Michael on board, we are well-positioned to navigate our growth and continue delivering on our mission to optimize patient outcomes through differentiated therapeutic approaches.”
Magee will lead and further strengthen Tris Pharma’s development and management of quality and compliance operations via the current Good Manufacturing Practices compliance function of the organization. His responsibilities will include ensuring adherence to, and compliance with, established company quality policies, practices and standard operating procedures and federal regulations, directing the quality of materials purchased, processed, manufactured and/or distributed by the company and overseeing and ensuring compliance with all appropriate regulatory agencies.
“I am excited to join the Tris Pharma team and partner across the organization to drive transformational growth in key areas of the business and optimize outcomes for the patients that we serve,” Magee said. “My passion for motivating teams to have a strong, organizationwide common purpose and sense of community aligns closely with Tris Pharma’s values. Along with the company’s transformative technology and differentiated products, as well as its drug development, manufacturing and commercial capabilities that Tris Pharma is expanding to reach patients globally, the opportunity to join the company was tremendous.”
Magee brings more than 25 years of experience to Tris Pharma, most recently serving as senior vice president of quality assurance at SCA Pharmaceuticals, where he led the multisite quality assurance division for the industry-leading 503B outsourcing company.
Prior to SCA, Magee held varying roles of increasing responsibility at Ferring Pharmaceuticals, Windtree Therapeutics and Johnson & Johnson, supporting quality assurance, regulatory compliance, operations, technical services and more across the companies.
“Michael brings a wealth of knowledge and a deep understanding of the regulatory and quality landscape, which will be instrumental in maintaining our unwavering commitment to developing therapeutics of the highest quality across ADHD, pain, addiction and neurological disorders,” Nicholas Cappuccino, chief quality officer, senior vice president of quality & compliance, at Tris Pharma, said. “I look forward to collaborating with Michael to further elevate our quality assurance and regulatory compliance practices.”